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Abstract

Keywords
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Colorectal cancer is the third most frequently reported malignancy and also the third leading
cancer-related cause of death worldwide. Lymph node evaluation, both preoperatively and
postoperatively, represents an important aspect of the diagnosis and therapeutic strategy in
colorectal cancer, such that an accurate preoperative staging is required for a correct therapeutic
strategy. Treatment of rectal cancer with positive lymph nodes, a very important predictive
prognostic parameter, is currently based on neoadjuvant chemoradiotherapy followed by total/
surgical mesorectal excision and adjuvant regimen.
Preoperative evaluation of the lymph node status in rectal cancer is based on endoscopic
ultrasound and magnetic resonance imaging, but their accuracy, specificity, and sensitivity still
require improvement. Postoperative evaluation also presents points of debate, especially related
to the role of sentinel lymph node mapping and their final implication, represented by detection
of micrometastases and isolated tumor cells. The pathologic interpretation of tumor deposits
represents other points in discussion. From a surgical perspective, extended lateral lymph node
dissection vs. abstinence and (neo)adjuvant therapeutic approach represent another unresolved
issue.
This review presents the major controversies existing today in the treatment and pathologic
interpretation of the lymph nodes in rectal cancer, the role/ indication and value of the lateral
pelvic lymph node dissection, and the postoperative interpretation of the value of the
micrometastatic disease and tumor deposits.


rectal cancer, lymph node evaluation, lateral lymph node dissection, sentinel lymph node
mapping, micrometastases
✓ Despite important progress made in the evaluation and prognostic interpretation of
lymph nodes in rectal cancer, many controversial and unresolved aspects remain,
requiring future clarification.
✓ An accurate interpretation requires better standardization than is now offered by
current staging systems, as suggested in this review.
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Introduction
Colorectal cancer is the third most common
malignancy reported at all sites, for both sexes, and also
the third leading cancer-related cause of death (1-3). The
incidence of rectal cancer in USA is about 12.3% per
100,000 people, with an estimated 39,610 new cases in
2015 (1, 4). Rectal topography represents between 1741% of the colorectal cancer cases, depending on the
patient’s age and sex (the proportion is higher in younger
patients and in men). Almost 33% of the rectal cancers
will have regional spread at the time of the diagnosis,
associated with a 5-year relative survival rate of 69.5%
(4). The T stage and high-grade pathology represent the
most important independent predictive factors for the
risk of lymph node involvement (5).
Lymph node involvement represents one of the most
important predictive parameters for survival: the 5-year
overall survival rates varies significantly from 74% if
nodal spread is absent (N0), to 64% if only 1-3 lymph
nodes are invaded (N1), and drops to 48% if more than 4
lymph nodes are invaded (N2); at the same time the local
recurrence rates will significantly increase from 9% if
N0, to 11% if N1, and 13% if N2 (6).
The treatment of rectal cancer with positive lymph
nodes is based in most centers on neoadjuvant
chemoradiotherapy, followed by rectal resection with
total mesorectal excision and adjuvant regimen. Some
centers apply extended lateral lymph nodes dissection.
Adequate treatment is based on the correct preoperative
evaluation of the lymph nodes basin which can be
influenced by many factors. The significance of an
adequate evaluation of the lymph node status in rectal
cancer is emphasized by the SEER analysis results that
show important declines in the 5-year relative survival
rates in cases with incorrect evaluation of the lymph
nodes (Nx): 23.8-89.4%, almost similar with N2 stage,
depending on the T stage of the tumor (7). The
evaluation of the lymph node involvement begins
preoperatively, but continues intraoperatively and with
postoperative histologic examination.

CT in predicting the N stage is low, between 53%-73%,
with an important percentage of cases overstaged (16%)
or understaged (10%) and a sensitivity of 17%-33% and
specificity of 81% (8, 9). In a randomized trial
FoxTROT, 83% of the pN+ were radiologically
classified as cN+, but with the same tendency of
overstaging the N stage (10). Nevertheless, the
abdominal CT appears to be the most frequently used
staging modality in rectal cancer centers (55% of centers
use abdominal CT in all cases of rectal cancer for staging
purposes) (11).
PET/CT manifests also a lower accuracy (60-66%),
specificity (81-90%), and sensitivity (33%) in detecting
lymph node invasion in colorectal cancer (8) and
represents the least common imaging method used for
preoperative staging of rectal cancer: only 1% of centers
use PET/CT for preoperative staging of all rectal cancer
cases (11). ERUS probably represents the best
preoperative staging modality for small rectal tumors (T1
and T2); the incidence of lymph node metastases in these
cases varies from 14.3% to 18.4% (12). However, the
usage of ERUS as a staging method in all rectal cancer
cases varies from 21% to 43% in colorectal cancer
centers (11).

Discussion
Pretherapeutic evaluation of the lymph node status
in rectal cancer
Preoperative evaluation of lymph node status in
rectal cancer is based on imaging modalities, clinical
examination having limited value. The main imaging
modalities used for TNM staging in rectal cancer are
endoscopic rectal ultrasound (ERUS), magnetic
resonance imaging (MRI), computed tomography (CT),
and
Positron
emission
tomography-computed
tomography (PET-CT). The accuracy of the abdominal

Figure 1. Endoscopic ultrasound in rectal cancer.
A. A rectal adenocarcinoma invading all layers
of the rectal wall (T3) with cleavage plane with
the prostate and peritumoral lymphadenopathy
B. Multiple suspected (round, hypoechogenic)
lymph nodes in a patient with a rectal
adenocarcinoma.
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ERUS has a 73%-76.47% accuracy in detecting
lymph node metastases in rectal cancer, with a sensitivity
of 52.94%-77% and a specificity of 70%-84.31% (13,
14). The value of ERUS in the N staging of rectal cancer
is influenced by the experience of the examiner and the
tumor morphology (i.e., it is lower in large-stenosing
tumors that do not allow the probe to pass through the
lumen). Also, it may be difficult to differentiate
malignant lymph nodes from benign ones, the malignant
appearance being suggested by the lymph node
morphology and size: round, hypoechogenic lymph
nodes, larger than 3-5 mm present a higher probability of
malignant colonization.
In order to improve the N staging, other modalities
may be used in association, such as fine-needle
aspiration cytology of the detected lymph nodes which
may increase the accuracy of the ERUS in detecting
colonized lymph nodes by up to 90%, with a sensitivity
of 87%, and a specificity of 100% (15). Also, using 3-D
endoscopic ultrasound, the accuracy of the nodal
detection may increase up to 87.3%, specificity up to
91.4%, and sensitivity up to 79.1% (16).
Endoscopic
Ultrasound
Elastography
(EUS
elastography) has proven to be a reliable method for
differentiating rectal adenomas from adenocarcinomas
(17), with an accuracy of 0.94, a sensitivity of 0.96, and
a specificity of 0.86. Furthermore, in differentiating
benign from malignant lymph nodes, elastography
presented a sensitivity of 70.2-85% and a specificity of
91-100%, depending on the elastography score, with the
lowest sensitivity (60%) and specificity (31.5%) for a
score 2 (18, 19). However, the role of ERUS
elastography in the evaluation of the lymph nodes in
rectal cancer remains to be demonstrated.

Figure 2. ERUS elastography: perirectal enlarged
lymph nodes with elastography hard aspect (blue)
in a patient with a rectal adenocarcinoma.
MRI is used for all cases of rectal cancer staging by
20-42% of the colorectal cancer centers (11). The
accuracy of MRI in detecting lymph node metastases in
rectal cancer varies from 68.49%-74.5% to 92%, with

61.76%-85.71%
sensitivity
and
57.78%-80.88%
specificity, similar to the ERUS (13, 20, 21). However,
the MRI presents the same problems of differentiating
between benign enlarged lymph nodes and malignant
lymph nodes, the diagnosis being based on the same
criteria as for ERUS (lymph nodes morphology and size)
(21).

Figure 3. MRI in rectal cancer: multiple suspected
lymph nodes in the presacral region (A) and on the
left pelvic sidewall region (B).
Pre and post-neoadjuvant treatment evaluation of the
lymph nodes represents an important objective and may
be realized using ERUS, MRI, or both as complementary
methods. Neoadjuvant chemoradiotherapy decreases the
tumoral volume and may also determine a downstaging,
thus becoming very important in evaluating the treatment
response; the lymph nodes post-neoadjuvant treatment
downstaging may be as high as 72.2% (22). The preneoadjuvant treatment accuracy of the lymph node
detection using ERUS was 56% but increases in the postneoadjuvant setting to 74%, while the MRI accuracy was
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the same in pre and post-neoadjuvant settings (74%), as
reported by Swartling et al. These authors concluded that
the staging accuracy was improved using the
combination of the ERUS and MRI (23).
Intraoperative evaluation of the lymph nodes;
extended lymphadenectomy in rectal cancer
Intraoperative evaluation of the lymph nodes in
rectal cancer raises two major points of contention: the
attitude over the potentially involved lymph nodes
located at a distance from the rectum, and the importance
of the lateral lymph nodes dissection.
Regarding the potential involvement of lymph nodes
located outside the regular area of drainage of a rectal
cancer, the recommendation is to follow the oncologic
principle of biopsy and, if possible, removal of all the
enlarged lymph nodes in order to reduce the tumoral
volume and correctly stage the case.
A special consideration must be accorded to lymph
nodes located at the origin of the inferior mesenteric
vascular package: ligation and section of the inferior
mesenteric artery and vein at their origin is not
mandatory, many surgeons performing it below the left
colic artery origin without any negative influence on the
distant survival or recurrence rate. Obviously, the
presence of an enlarged lymph node at this level requires
ligation of the inferior mesenteric artery at its origin and
removal of the lymph nodes.
Regarding perirectal (intra-mesorectal) lymph nodes,
these may be palpated in some cases but intraoperative
biopsy is not recommended, requiring sectioning of the
mesorectal fascia which may compromise the oncologic
results. Quirke et al. have demonstrated that the plane of
surgery achieved during rectal resection for cancer has
an important influence on the local recurrence rate and
distant survival: a 3-year 4% local recurrence rate if the
mesorectal plane was achieved, compared to 13% if the
muscularis propria plane was entered during surgery,
respectively a 79% 3-year disease-free survival rate, if
the mesorectal plane was achieved, compared to 70%75% if the mesorectal plane was compromised during
surgery (24).
Probably the most debatable point relates to the
extended lateral (pelvic) lymph node dissection. Western
surgeons do not perform and do not routinely
recommend lateral lymph node dissection in rectal
cancer, considering metastases in these lymph nodes as
systemic spread of the disease; consequently, they are
treated with chemoradiotherapy. Moreover, the
MERCURY study group has found through MRI an
incidence of 11.7% suspicious lateral lymph nodes, but
the 5-year disease free survival was influenced only in

the cases receiving primary surgery (42% 5-year DFS)
and not in the group receiving neoadjuvant treatment,
which supports the above opinion (25).
Extended lateral lymph node dissection is more
common among Eastern surgeons, especially in Japan.
The incidence of lateral lymph node metastases varies
from 10% to 25% of the cases (26-28) (11% in the study
of Dong et al., 14.6% in Wu et al., and 17% in the series
of reports by Ueno et al.) (26, 27, 29), but the presence
of micrometastases was demonstrated in another 4% of
the cases where the positivity of the lymph node was not
suspected after initial histologic evaluation (30).
The risk of lateral lymph node involvement
increases in low rectal cancers (below peritoneal
reflection) with the T stage, circumferential rectal wall
involvement, tumor size >5 cm, advanced tumor
infiltration and poor differentiation (26, 27), and also
with the presence of the positive mesorectal lymph nodes
(28), but this is not mandatory since Ueno et al. have
found that 24% of the cases (10 out of 41 cases) with
invasion in the lateral pelvic lymph nodes had no
invasion in the mesorectal lymph nodes (29).
Extended lymph nodes resection, including the
origin of the inferior mesenteric artery and pelvic
sidewall dissection, has been associated with an
improved 5-year survival for all stages (overall 68% 5year survival rate for extended lymphadenectomy vs
42.9% for conventional resection) as reported in Dong et
al. (26). In a retrospective study, Shirouzu et al. found
that TME associated with lateral lymph node dissection
produced better results than conventional surgery, but
only in Dukes C stage: 13.3%-16.7% local recurrence
rate vs 25% for conventional surgery (31). Wu et al. have
also demonstrated that the presence of lateral lymph
node metastasis is associated with a significantly
increased risk of local recurrence (64.3%) compared with
patients without lateral lymph node metastases (11%),
and a significantly lower median survival rate (38 ± 6.7
months vs 80.9±2.1 months) (27). Ueno et al. have also
found a lower 5-year survival rate in cases with lateral
lymph node involvement, only 32%-42%, and an
increased risk of local recurrence (56.8%), in cases
without distant metastases (28, 29).
The main selection criteria for lateral pelvic
dissection in rectal cancer are: advanced rectal cancers
(T3 and resectable T4 and some advanced T2 cancers,
stage III on the TME specimen), located below the
peritoneal reflection, on a suitable patient, without
distant or peritoneal metastases (26, 32). Wu et al.
recommend lateral lymphadenectomy for tumors larger
than 5 cm in diameter (27, 32), although Ueno et al.
found no significant correlation between tumor diameter
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and lateral lymph nodes invasion (29). Ueno et al. also
found that the increased number of invaded lymph nodes
is associated with an increased risk of lateral lymph node
metastases (2/3 of the cases with lateral lymph node
involvement had 4 or more positive lymph nodes), and a
lower long-distance survival (4% for 4 or more positive
lymph nodes compared with 75% for less than 3
involved lymph nodes) (28, 29).
In spite of the apparently better results of the
extended lymph node dissection, the higher morbidity,
especially in terms of genitourinary dysfunction, requires
supplementary criteria for case-selection for lateral
lymph nodes dissection.
However, with the lateral lymph node dissection and
autonomic nerve preservation, better results were
obtained in terms of perioperative results (31), but results
appear to be better in terms of urinary function and not
so good in terms of genital impairment (33).
The size of the pelvic lymph nodes appears to be an
important criterion; on histopathologic analysis on a cutoff of 8.4 mm for the long axis and 5.4 mm for the short
axis, Ishida et al. obtained an accuracy of 71.9% (for the
long axis) and 72.8% (for the short axis, respectively) in
predicting the risk of lateral lymph nodes metastases
(34). However, a more recent study demonstrated a
lower positive predictive value of the lymph node size
for lateral lymph nodes compared to perirectal
(mesorectal) lymph nodes (35).
Using the same criteria, Matsuoka et al. consider
that an ovoid shape with transverse axis larger than 5
mm of the lymph nodes identified on MRI represents an
optimal criterion for lateral dissection in rectal cancer
(36). Ueno et al. have also found that in cases with lateral
lymph node invasion, the diameter of the lymph nodes
was statistically larger than the diameter of the noninvaded lateral lymph nodes (8.5±4.1 vs 6.0±2.8 mm);
the incidence of lateral lymph nodes invasion increased
progressively with the size of the lymph nodes from
3.6% in cases with lymph nodes < 5 mm, up to 34% in
cases with lymph nodes larger than 10 mm (29). Quadros
et al. have used intraoperatively a radiotracer and a blue
dye stain which allowed them to find with 100%
accuracy and sensitivity in 37.1% of the cases metastatic
lymph nodes in the retroperitoneal and lateral pelvic
area, with an upstaging rate of 11.1% (out of which 5.5%
were due to micrometastases identification) (32).
In conclusion, the debate over the necessity of lateral
pelvic lymph node dissection remains open, even if the
meta-analysis performed by Cheng et al. found no
significant difference in terms of 5-year survival and
recurrence rate, but the postoperative morbidity was
higher in cases with lateral dissection performed (37).

Establishing clear preoperative criteria for indication of
the lateral lymph nodes dissection remains, also, an open
discussion.
Pathologic evaluation: sentinel lymph node
mapping and micrometastases significance in rectal
cancer
It is now well recognized that the number of the
pathologically examined lymph nodes has a great
influence on colorectal cancer staging, and ultimately on
distant survival of the patients (38-40). Starting with the
sixth edition of the AJCC staging system it was
established that a minimum of 12 lymph nodes must be
histologically evaluated in order to ensure an adequate N
staging, a recommendation that was maintained in the
subsequent seventh edition and in the current guidelines
for rectal cancer (39, 41, 42). At this point, the
histological examination of fewer than 12 lymph nodes is
considered a risk for residual disease and incorrect
downstaging and an adjuvant chemotherapy protocol
must be employed (38-41). In spite of the
recommendations there are many situations in which the
minimum number of 12 lymph nodes is not reached,
even in the most developed care systems (38, 43, 44, 45),
negatively influencing the quality of the staging. Many
factors influence the number of the lymph nodes
examined on a resection specimen for rectal cancer (41,
43, 46), out of which the neoadjuvant therapy appears to
be a specific one (47). There are many modalities trying
to improve the staging, including the injection of a blue
dye in the inferior mesenteric artery (48) in order to
identify more stained lymph nodes; NCCN guidelines for
rectal cancer recommend, in case of fewer than 12 lymph
nodes identified, for the pathologist to review the
specimen in an attempt to identify more lymph nodes
(41). Probably the most debatable method trying to
improve the pN staging in rectal cancer remains the
sentinel lymph node mapping; however, current
guidelines recommend caution in interpretation of the
results (41).
Several methods have been used for identification of
the SLN in rectal cancer: in vivo or ex vivo techniques,
different staining dyers or radiotracers, even different
techniques of pathologic evaluation (seriate sections,
usual hematoxylin-eosine staining method, immunehistochemistry or polymerase-chain reaction) (49-55), all
leading to a lack of uniformity and making finding a
common and reproducible path difficult.
The detection rate of the SLN varies from 61.9% to
97.8%-100%, the sensitivity 50%-58.3% to-80%- 93.7%,
with a false negative rate of 3.84%-10.7% to 18.18%20%, and an upstaging rate varying from 4.76%-12.5%
to 29%-37.5%. The results were better when the study
included the colon and the rectum cases together (49-55).
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As a consequence, the different detection rate,
sensitivity, and specificity of these methods represent
other reasons for which SLN mapping is not a method
sufficiently good to be recommended as a guideline,
even though most studies have demonstrated some
degree of upstaging. The main advantage, present in
most of these studies, is represented by the identification
of a higher number of lymph nodes submitted to
pathologic evaluation than conventional, non-staining
methods (49-55). Making the decision even more
difficult, the significance of the micrometastases and
isolated tumor cells identified on the examined lymph
nodes only by IHC or RT-PCR is still up for debate.
The incidence of micrometastases varies, depending
on the examination technique, from 25.5-30% to 54-60%
if IHC or RT-PCR technique, respectively, is used for
detection (56-58).
Wang et al., have found a significant drop in the 5-

Conclusions
Despite important progress made in the evaluation
and prognostic interpretation of lymph nodes in rectal
cancer, many controversial and unresolved aspects
remain, requiring future clarification. However, accurate
interpretation requires better standardization than is now
offered by current staging systems, as demonstrated by
the present studies.
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